NR2F1 and osteosarcoma: NR2F1-AS1 has been reported to promote the growth of hepatocellular carcinoma (Huang H. et al., 2018), thyroid carcinoma (Yang et al., 2020), osteosarcoma (Li et al., 2019) and breast cancer (Sanchez et al., 2020).